lenalidomide

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

A discussion with Matthew Matasar, MD, MS, on using loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell #lymphoma. #DLBCL #lymsm | @DrMatasar @RutgersCancer https://t.co/LKM8ZtGFIq (@TargetedOnc)

Humoral immune reconstitution following daratumumab, carfilzomib, lenalidomide, & dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and MRD-response-adapted treatment cessation https://t.co/06j16E5v3f @End_myeloma @TMSchmidtMD #mmsm (@e_JHaem)

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm (@mtmdphd)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

Ciltaca-cel significantly improved PFS over SOC pomalidomide, bortezomib, & dexamethasone or daratumumab, pomalidomide, & dexamethasone in pts w/ lenalidomide-refractory MM who received 1 to 3 prior lines of therapy. @bhemato @MedicalCollege #mmsm https://t.co/Pav2681nn1 (@OncLive)

Ciltaca-cel significantly improved PFS over SOC pomalidomide, bortezomib, & dexamethasone or daratumumab, pomalidomide, & dexamethasone in pts w/ lenalidomide-refractory MM who received 1 to 3 prior lines of therapy. @bhemato @MedicalCollege #mmsm https://t.co/CGAxsgJTiz (@OncLive)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm (@mtmdphd)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

Then you should know that a drug company did not discover or invent the use of imids like Revlimid for myeloma. It required very little investment by the drug company. Celgene stumbled into it. Here's the story. https://t.co/CahZNv6wpJ (@DavidP4AD)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm (@mtmdphd)

#17ICML Brentuximab in DLBCL. The best response is combining BV plus lenalidomide (31% CRR in R/R DLBCL. Remember 1/3 of patients will express CD30+. @GuiperiniMD @Denicasuri @GELL01433166 (@hematologo)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUkfVv Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

Huge congratulations to Multiple Myeloma Hub steering committee member @H_Einsele, selected for one of the #EHA2023 best abstracts awards! Abstract S100: First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory MM #mmsm (@MM_Hub)

For US #HCPs attending #EHA2023, tune in to Dr. Hermann Einsele’s (@H_Einsele) presentation on first results from the Phase 3 CARTITUDE-4 study evaluating a BCMA CAR-T therapy in patients with relapsed and lenalidomide-refractory #MultipleMyeloma. (@JanssenUSOncMed)

CONGRESS| #EHA2023 @AnnaSureda5 presents results from 2 cohorts in EPCORE NH2 investigating epcoritamab+rituximab & lenalidomide in patients with R/R FL. This combination showed potent anti-tumor activity and a manageable safety profile in patients with high-risk disease #lymsm (@lymphomahub)

My mentor @AnnaSureda5 is talking about epcoritamab + lenalidomide + Rituximab en Follicular Lymphoma. #EHA2023 (@hematologo)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

Cilta-cel Possesses Potential to Be New SOC for Lenalidomide-refractory Myeloma After First Relapse @bhemato @MedicalCollege @ASCO #ASCO23 #ASCO2023 #mmsm https://t.co/VAsrgnIrGX (@OncLive)

Question: For a fit 47 y/o Pt with relapse myeloma t(11;14) refractory to lenalidomide! What will be ur next option based on recent data from #ASCO23? #mmsm #MedTwitter #MedEd #USMIRC #myeloma (@Abdallah81MD)

Cilta-cel vs Standard of Care (SOC) in Lenalidomide-Refractory Myeloma (1-3 prior lines). Median PFS (mPFS) 11.8 mo for SOC; mPFS not reached for cilta-cel (HR=0.26) at median f/u 15.9 mo. All subgroups benefitted, incl high-risk #mmsm ⁦@IMFmyeloma⁩ https://t.co/fExPbVaeKd (@DrOlaLandgren)

Now in @NEJM, read a peer-reviewed publication authored by Drs. Jesús San-Miguel & Hermann Einsele (@H_Einsele) reporting first results from Phase 3 CARTITUDE-4 study evaluating BCMA CAR-T therapy in patients with relapsed & lenalidomide-refractory #MultipleMyeloma. For US #HCPs. (@JanssenUSOncMed)

On heels of #ASCO23 presentation by @bhemato: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma | @NEJM #mmsm #myeloma https://t.co/UA9xtQ6cdU (@BldCancerDoc)

CARTITUDE-4 results unveiled at #ASCO23: PFS benefit seen with ciltacabtagene autoleucel in lenalidomide-refractory #multiplemyeloma: https://t.co/7PnPHKhMgb #ASCODailyNews @bhemato #mmsm (@ASCO)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

For US #HCPs at #ASCO23, don’t miss Dr. Binod Dhakal (@bhemato) present the first results from the Phase 3 CARTITUDE-4 study investigating a BCMA CAR-T therapy in patients with relapsed and lenalidomide-refractory #MultipleMyeloma. (@JanssenUSOncMed)

Final results of a multicenter phase II trial of lenalidomide plus CHOEP in untreated PTCL: moderate response rates with considerable haematologic toxicity https://t.co/jdWbhm0r1v #lymsm @lymphomaphilia @NicolaisRobert @DrJulieVose @NehaMehtaShahMD @luuqpham @BradHaverkos (@BrJHaem)

Azacitidine, lenalidomide and DLI for relapse of #MDS, #AML and #CMML after allogeneic transplant: the Azalena-Trial @KrogerNicolaus @Haematologica #leusm #MDSsm #MPNsm MDS(n=24), AML(n=23), CMML (n=3) ORR 56%, 50% CR (80% durable) mOS 21mo, 1-yr OS 65% https://t.co/MS5BugzOl7 (@Wang_Yu_Hung)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

📣Our latest @TheIACH Journal Club: Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) Now available on-demand! 📽️View the full webinar for FREE https://t.co/rI1oBq60nF @thanosdimop @Mohty_EBMT (@TheIACH)

Increased CXCL10 is seen at one-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy #mmsm @MCWCancerCenter⁩ ⁦@adsouza_md⁩ ⁦⁦@mpasca⁩ https://t.co/0NlUaSQsEp (@MeeraMohanMD)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

📣Join us NOW! ⬇️⬇️⬇️ https://t.co/y9wgvPS088 Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) ✍️FREE registration! @thanosdimop @Mohty_EBMT (@TheIACH)

📣Join us TOMORROW for @TheIACH Journal Club: Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) FREE registration⬇️ https://t.co/7tD8XQnQ2F Tuesday, May 23 2023 6pm Paris, 12pm NY @thanosdimop @Mohty_EBMT (@TheIACH)

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)

Just had a patient with ALL after 8 years of Revlimid on ECOG smoldering trial. That should be balanced against number-to-treat to prevent renal failure(reversible?) and bony lesions. @SagarLonialMD @VincentRK @myelomaMD (@EhsanMalekMD)